Michael A. Pulsipher

25.6k total citations · 2 hit papers
253 papers, 7.6k citations indexed

About

Michael A. Pulsipher is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Michael A. Pulsipher has authored 253 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Hematology, 97 papers in Public Health, Environmental and Occupational Health and 69 papers in Oncology. Recurrent topics in Michael A. Pulsipher's work include Hematopoietic Stem Cell Transplantation (149 papers), Acute Lymphoblastic Leukemia research (83 papers) and CAR-T cell therapy research (46 papers). Michael A. Pulsipher is often cited by papers focused on Hematopoietic Stem Cell Transplantation (149 papers), Acute Lymphoblastic Leukemia research (83 papers) and CAR-T cell therapy research (46 papers). Michael A. Pulsipher collaborates with scholars based in United States, Canada and Germany. Michael A. Pulsipher's co-authors include Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Barry E. Storer, Michael B. Maris, Thomas R. Chauncey, Richard T. Maziarz, Amelia Langston, Mohamed L. Sorror and Stephan A. Grupp and has published in prestigious journals such as JAMA, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Michael A. Pulsipher

246 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunogenicity of CAR T cells in cancer therapy

2021 208 citations Michael A. Pulsipher, Nirali N. Shah et al. profile →
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

2021 207 citations Patrick A. Brown, Lingyun Ji et al. profile →

Peers

Countries citing papers authored by Michael A. Pulsipher

Since Specialization

Citations

This map shows the geographic impact of Michael A. Pulsipher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Pulsipher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Pulsipher more than expected).

Fields of papers citing papers by Michael A. Pulsipher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Pulsipher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Pulsipher. The network helps show where Michael A. Pulsipher may publish in the future.

Co-authorship network of co-authors of Michael A. Pulsipher

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Pulsipher. A scholar is included among the top collaborators of Michael A. Pulsipher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Pulsipher. Michael A. Pulsipher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement 2025 ·HemaSphere ·Adam J. Lamble, Sandra D. Bohling, Kara L. Davis, Aimee C. Talleur, Kevin O. McNerney, (unknown), Priya Kumar, Rebecca Thomas, Hao‐Wei Wang, Constance M. Yuan, Elad Jacoby, André Baruchel, Sara Ghorashian, Michael A. Pulsipher, Liora M. Schultz, Rebecca Gardner, Nirali N. Shah	0
2	Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL 2025 ·Blood ·Colleen Annesley, Kristy Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K. Agrawal, Christopher T. Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, (unknown), Michael C. Jensen, Julie R. Park, Rebecca Gardner	2
3	Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry 2025 ·Blood Advances ·Samuel John, Kevin J. Curran, (unknown), Amy K. Keating, Susanne H.C. Baumeister, Sarah Nikiforow, Timothy Driscoll, Amy Moskop, Kevin O. McNerney, Christine L. Phillips, Michael A. Pulsipher, Emily M. Hsieh, Rayne H. Rouce, Marcelo C. Pasquini, Ranjan Tiwari, Jennifer Willert, (unknown), Joerg Krueger, Erin Guest, Stephan A. Grupp	0
4	Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy 2024 ·Transplantation and Cellular Therapy ·Raheel Iftikhar, (unknown), Amy E. DeZern, Michael A. Pulsipher, Nelli Bejanyan, Lauri M. Burroughs, Mohamed A. Kharfan‐Dabaja, Sally Arai, Adetola A. Kassim, (unknown), Blachy J. Dávila Saldaña, Mahmoud Aljurf, Mehdi Hamadani, Paul A. Carpenter, Joseph H. Antin	5
5	Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication 2024 ·Nature Communications ·Michael D. Keller, Stefan Schattgen, Shanmuganathan Chandrakasan, E. Kaitlynn Allen, (unknown), Christopher A. Lazarski, Muna Qayed, Haili Lang, Patrick J. Hanley, (unknown), Sung‐Yun Pai, Suhag Parikh, Seth Berger, Stephen Gottschalk, Michael A. Pulsipher, Paul G. Thomas, Catherine M. Bollard	3
6	Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL 2024 ·Blood Advances ·Colleen Annesley, Adam J. Lamble, Corinne Summers, Michael A. Pulsipher, Alan S. Wayne, Julie Rivers, Wenjun Huang, (unknown), Qian Wu, Kristy Seidel, Stephanie Mgebroff, Christopher T. Brown, Catherine Lindgren, Julie R. Park, Michael C. Jensen, Rebecca Gardner	2
7	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience 2022 ·Bone Marrow Transplantation ·Jeffrey R. Andolina, Yi‐Cheng Wang, Lingyun Ji, David R. Freyer, John E. Levine, Michael A. Pulsipher, Alan S. Gamis, Richard Aplenc, Michael Roth, Lauren Harrison, Mitchell S. Cairo	6
8	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation 2020 ·Science Translational Medicine ·Winghing Wong, Sima Bhatt, Kathryn Trinkaus, Iskra Pusic, Kevin Elliott, Nitin Mahajan, Fei Wan, Galen E. Switzer, Dennis L. Confer, John F. DiPersio, Michael A. Pulsipher, Nirali N. Shah, Jennifer A. Sees, (unknown), Jamie R. Blundell, Bronwen E. Shaw, Todd E. Druley	36
9	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study 2020 ·UNC Libraries ·Brandon Hayes‐Lattin, (unknown), Michael Linenberger, Galen E. Switzer, Mark R. Litzow, Dennis L. Confer, (unknown), Brian J. Bolwell, Marcie Riches, Rebecca Drexler, Mary M. Horowitz, Roberta King, Bronwen E. Shaw, (unknown), (unknown), Michael A. Pulsipher, Scott D. Rowley	1
10	Bilateral retinal detachment after chimeric antigen receptor T-cell therapy 2020 ·Blood Advances ·Christopher Denton, William S. Gange, Hisham Abdel‐Azim, Sonata Jodele, Neena Kapoor, Matthew J. Oberley, Kenneth Wong, Jonathan Kim, (unknown), (unknown), K V Chalam, (unknown), Rebecca Gardner, Michael A. Pulsipher, Michael C. Jensen, Aaron Nagiel	18
11	2019 ASPHO ABSTRACTS 2019 ·Pediatric Blood & Cancer ·Michael A. Pulsipher, (unknown), Máire F. Quigley, (unknown), (unknown), Theodore W. Laetsch, (unknown)	10
12	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 2019 ·Blood ·Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Michael J. Borowitz, Elizabeth A. Raetz, Gerhard Zugmaier, Elad Sharon, Lia Gore, James A. Whitlock, Michael A. Pulsipher, Stephen P. Hunger, Mignon L. Loh	51
13	CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia 2017 ·Blood ·Theodore W. Laetsch, Shannon L. Maude, Stephan A. Grupp, Michael W. Boyer, Andrew C. Harris, Muna Qayed, Christine L. Phillips, Michael A. Pulsipher, Henrique Bittencourt, Patricia A. Wood, Karen Thudium Mueller, (unknown), Carl H. June, Bruce L. Levine, Hidefumi Hiramatsu	14
14	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis 2016 ·Blood ·Shannon L. Maude, Michael A. Pulsipher, Michael W. Boyer, Stephan A. Grupp, Stella M. Davies, Christine L. Phillips, Michael R. Verneris, Keith J. August, Krysta Schlis, Timothy A. Driscoll, Rajen Mody, Christian M. Capitini, Carl H. June, Bruce L. Levine, Patricia A. Wood, Lan Yi, John E. Levine	59
15	Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose 2009 ·Blood ·Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Susan F. Leitman, Paolo Anderlini, John P. Klein, Mary M. Horowitz, J. Philip Miller, Roberta King, Dennis L. Confer	111
16	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning 2008 ·Journal of Clinical Oncology ·Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Richard T. Maziarz, Edward Agura, Thomas R. Chauncey, Michael A. Pulsipher, Peter A. McSweeney, James C. Wade, Benedetto Bruno, Amelia Langston, Jerald P. Radich, Dietger Niederwieser, Karl G. Blume, Rainer Storb, David G. Maloney	182
17	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting 2008 ·Blood ·Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer Storb, David G. Maloney	71
18	Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation 2008 ·Cancer ·Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, David G. Maloney, Thomas R. Chauncey, Amelia Langston, Richard T. Maziarz, Michael A. Pulsipher, Peter A. McSweeney, Rainer Storb	199
19	Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria 2006 ·Blood ·John D. Phillips, David P. Steensma, Michael A. Pulsipher, Gerald J. Spangrude, James P. Kushner	102
20	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant 2003 ·Biology of Blood and Marrow Transplantation ·(unknown), Brenda M. Sandmaier, David G. Maloney, Michael B. Maris, Theodore A. Gooley, Thomas R. Chauncey, Ute Hegenbart, Peter A. McSweeney, Monic J. Stuart, Stephen J. Forman, Edward Agura, Michael A. Pulsipher, Karl G. Blume, Dietger Niederwieser, Rainer Storb	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact